Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Big Is The Antidiabetics Market Today And What Is Its Future Size?

In recent times, the antidiabetics market has seen a swift expansion. The projection suggests that its value will rise from $76.03 billion in 2024 to $84.07 billion in 2025, presenting a compound annual growth rate (CAGR) of 10.6%. The historical growth of this market is due to several factors. These include the escalating prevalence of diabetes worldwide, breakthroughs in medication development, heightened awareness and detection rate, government support, a rising elderly population, inactive lifestyles, and the growth in health care spending.

In the coming years, rapid expansion is anticipated for the antidiabetics market, its size expected to reach $127.48 billion by 2029, propelled by a compound annual growth rate (CAGR) of 11.0%. This acceleration during the forecast period can be attributed to several factors such as the rising occurrence of diabetes, increased awareness and diagnosis, escalating healthcare expenditure, an increasing aged population, and the implementation of government health policies and initiatives. Key trends to watch out for during this forecast period include the surge in GLP-1 receptor agonists and SGLT2 inhibitors, expansion of biologics and biosimilars, emphasis on preventive healthcare, growth of emerging markets, and integration of technology.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18225&type=smp

Which Demand Drivers Are Strengthening The Antidiabetics Market?

The growth of the antidiabetic market is anticipated to be spurred by the increasing prevalence of lifestyle-related health complications. These complications arise or become more severe due to habits such as a poor diet, inadequate physical activity, smoking, and excessive drinking. The escalation of these health issues is attributed to unhealthy eating habits, lack of physical exercise, and heightened stress levels. Antidiabetic drugs can aid in managing these diseases, such as obesity and metabolic syndrome, by enhancing insulin responsiveness and regulating blood glucose levels. For example, in March 2022, the Switzerland-based international organization, World Health Organization, reported that about 1 billion people globally, including 650 million adults, 340 million teenagers, and 39 million children, are obese. This figure is continually increasing. It is estimated that by 2025, about 167 million adults and children will experience health problems due to overweight or obesity. Consequently, the escalating prevalence of these lifestyle-related illnesses is propelling the growth of the antidiabetic market.

Which Segment Accounts For The Largest Share In The Antidiabetics Market?

The antidiabeticsmarket covered in this report is segmented –

1) By Drug Class: Insulin; GLP-1 Receptor Agonists; DPP- 4 Inhibitors; SGLT2 Inhibitors; Other Drug Classes,

2) By Diabetes Type: Type 1; Type 2

3) By Patient Population: Antidiabetics For Pediatrics; Antidiabetics For Adults; Antidiabetics For Geriatrics

4) By Route Of Administration: Antidiabetics Administration Through Insulin Syringes Or Insulin Pens; Antidiabetics Administration Through Insulin Pumps; Intravenous Antidiabetics Infusion; Oral Antidiabetics Administration; Other Routes Of Antidiabetics Administration

5) By Distribution Channel: Online Pharmacies; Hospital Pharmacies; Retail Pharmacies

Subsegments:

1) By Insulin: Rapid-Acting Insulin; Short-Acting Insulin; Intermediate-Acting Insulin; Long-Acting Insulin; Premixed Insulin

2) By GLP-1 Receptor Agonists: Exenatide; Liraglutide; Dulaglutide; Semaglutide; Lixisenatide

3) By DPP-4 Inhibitors: Sitagliptin; Saxagliptin; Linagliptin; Alogliptin

4) By SGLT2 Inhibitors: Canagliflozin; Dapagliflozin; Empagliflozin; Ertugliflozin

5) By Other Drug Classes: Sulfonylureas; Thiazolidinediones (TZDs); Alpha-Glucosidase Inhibitors; Meglitinides; GLP-1/Insulin Combination Therapy

Which Long-Term Trends Will Play A Crucial Role In The Antidiabetics Market?

A variety of top-tier corporations in the antidiabetics market are innovating and enhancing their product line, specifically through the creation of advanced solutions like anti-diabetic biosimilars. These are designed to enhance glucose monitoring, minimize incidences of cardiovascular complications, and provide more efficient therapy alternatives for individuals suffering from diabetes. These biosimilars are equivalent to already approved benchmark drugs used for diabetes treatment, displaying similar safety, efficacy, and quality parameters. To illustrate this, in January 2024, Glenmark Pharmaceuticals Limited, a pharmaceutical firm based in India, undertook the inauguration of the first biosimilar for the anti-diabetic drug, Liraglutide. This biosimilar, marketed under the brand name Lirafit, enables enhanced glucose management in adults diagnosed with type 2 diabetes mellitus. Clinical studies have demonstrated its effectiveness in reducing glucose-related parameters, promoting weight loss, and boosting cardiac safety. As a GLP-1 receptor catalyst, it promotes insulin secretion dependent on glucose and minimizes unsuitable glucagon secretion. It has obtained global approval for the administration of type 2 diabetes in adults.

Which Companies Hold A Competitive Edge In The 823 Market?

Major companies operating in the antidiabetics market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited, GSK plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen, Vertex Pharmaceuticals Incorporated, Servier Laboratories, Sun Pharmaceutical Industries Limited, Cipla Limited, Dr. Reddy’s Laboratories, Lupin Limited, Torrent Pharmaceuticals Ltd, Biocon Limited, Glenmark Pharmaceuticals Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Which Region Is Forecasted To Lead The Antidiabetics Market In The Coming Years?

North America was the largest region in the antidiabetics market in 2024. The regions covered in the antidiabetics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=18225&type=smp

Browse Through More Reports Similar to the Global Antidiabetics Market 2025, By The Business Research Company

Anti Hypertensive Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report

Antithrombotic Drugs Market 2025

https://www.thebusinessresearchcompany.com/report/antithrombotic-drugs-market

Anti Asthmatics And Copd Drugs Market 2025

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model